Hysteroscopic-guided Endometrial Injury in Women With Unexplained Infertility
How to cite
Shokeir, Tarek. 2014. "Hysteroscopic-guided Endometrial Injury in Women With Unexplained Infertility." AEA RCT Registry. AEARCTR-0000532. https://doi.org/10.1257/rct.532-2.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
Since an impairment of endometrial receptivity may be a potential cause of subfertility in women diagnosed with unexplained infertility (UI), therefore, it is supposed that local endometrial injury may help a group of women with UI. Based on this concept, the aim of this trial is to evaluate the efficacy of local endometrial injury (site-specific hysteroscopic-guided) in a group of women with UI undergoing expectant management versus no intervention.
Intervention
Study population:-
In a prospective randomized open-labeled study, this trial will be conducted at the Department of Obstetrics & Gynecology, Mansoura University Hospital. The study will be approved by the Ethics Committee of Mansoura University On Human Investigations, and all subjects will give written informed consent.
One hundred women between 18-39 years old who had been infertile (primary or secondary) for at least 1 year will be recruited. A complete evaluation will be conducted on all patients including history & physical examination. Semen analysis for all male partners will be done and WHO criteria will be used to confirm normality. Tubal patency will be confirmed by hysterosalpingography (HSG) and/or laparoscopy. All patients recruited for the study will have regular ovulatory cycles confirmed by mid-luteal serum progesterone assay and diagnosis of UI will be confirmed in all cases. A standard transvaginal sonography (TVS) will be done for all participants to rule out any pelvic pathology.
In addition to abnormal semen analysis and HSG, exclusion criteria will include female age over 40 years, presence of uterine fibroids, pelvic endometriosis, basal FSH of >11 mIU/ml, hypo-or hyperthyroidism, hyperprolactinemia, previous exposure to any ovulation induction agents in the previous 3 months before the trial, and women who refuse to participate in this trial or not aiming to complete the follow-up.
Study protocol:
A single site-specific hysteroscopic injury procedure (Snip) will be performed using an office hysteroscopy (Karl Storz, Germany). By means of vaginoscopy, a 2.9 mm. continuous-flow diagnostic hysteroscope with a 5 Fr. working-channel is guided through the cervical canal with normal saline as distension medium, with flow manually regulated through the key of the hysteroscopic sheath.
The examination of the uterine cavity begins by observing its regularity, paying special attention to the presence of intrauterine malformations or morphologic alterations such as submucous myomas, or uterine septa. Subsequently, A claw forceps will be introduced through a 2.2 mm working channel, and will be used to generate a local injury on the anterior or posterior endometrium (Endometrial Snip) at midline 10-15 mm from the fundus on D4 to D7 of the ongoing menstrual cycle. The depth and width of the injured site will be about 2x2 mm (i.e a single bite of the claw forceps). No premedications, antibiotics or hemostatics will be given after the procedure.
Natural cycle folliculometry + timed sexual intercourse will be offered for all participants for the ongoing and the immediate subsequent cycles. Once the leading ovarian follicle will reach a size of at least 16 mm, 10,000 IU of hCG will be administered to trigger ovulation.
Experimental design
In a prospective randomized open-labeled study, this trial will be conducted at the Department of Obstetrics & Gynecology, Mansoura University Hospital. The study will be approved by the Ethics Committee of Mansoura University On Human Investigations, and all subjects will give written informed consent.
One hundred women between 18-39 years old who had been infertile (primary or secondary) for at least 1 year will be recruited. A complete evaluation will be conducted on all patients including history & physical examination. Semen analysis for all male partners will be done and WHO criteria will be used to confirm normality. Tubal patency will be confirmed by hysterosalpingography (HSG) and/or laparoscopy. All patients recruited for the study will have regular ovulatory cycles confirmed by mid-luteal serum progesterone assay and diagnosis of UI will be confirmed in all cases. A standard transvaginal sonography (TVS) will be done for all participants to rule out any pelvic pathology.
In addition to abnormal semen analysis and HSG, exclusion criteria will include female age over 40 years, presence of uterine fibroids, pelvic endometriosis, basal FSH of >11 mIU/ml, hypo-or hyperthyroidism, hyperprolactinemia, previous exposure to any ovulation induction agents in the previous 3 months before the trial, and women who refuse to participate in this trial or not aiming to complete the follow-up.
Study protocol:
A single site-specific hysteroscopic injury procedure (Snip) will be performed using an office hysteroscopy (Karl Storz, Germany). By means of vaginoscopy, a 2.9 mm. continuous-flow diagnostic hysteroscope with a 5 Fr. working-channel is guided through the cervical canal with normal saline as distension medium, with flow manually regulated through the key of the hysteroscopic sheath.
The examination of the uterine cavity begins by observing its regularity, paying special attention to the presence of intrauterine malformations or morphologic alterations such as submucous myomas, or uterine septa. Subsequently, A claw forceps will be introduced through a 2.2 mm working channel, and will be used to generate a local injury on the anterior or posterior endometrium (Endometrial Snip) at midline 10-15 mm from the fundus on D4 to D7 of the ongoing menstrual cycle. The depth and width of the injured site will be about 2x2 mm (i.e a single bite of the claw forceps). No premedications, antibiotics or hemostatics will be given after the procedure.
Natural cycle folliculometry + timed sexual intercourse will be offered for all participants for the ongoing and the immediate subsequent cycles. Once the leading ovarian follicle will reach a size of at least 16 mm, 10,000 IU of hCG will be administered to trigger ovulation.
Design details
Cited by
No citation data available for this registration yet.